InflaRx N.V. | CIK:0001708688 | 3

  • Filed: 3/29/2018
  • Entity registrant name: InflaRx N.V. (CIK: 0001708688)
  • Generator: Novaworks Software
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1708688/000095010318003977/0000950103-18-003977-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1708688/000095010318003977/ifrx-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001708688
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory

    Research expenses are recognized as expense when they are incurred. They comprise third party services, wages and salaries, cost of materials, depreciation and amortization of relevant equipment and intangibles as well as overhead.

     

    Development expenses must be capitalized if the criteria of IAS 38 are met. In the periods presented, no development expenses were capitalized because management does not believe all the recognition criteria of IAS 38 had been met. This assessment is due to the general uncertainties in drug development and the unpredictability of regulatory requirements.

     

    Intellectual property-related expenses for patents are part of the expenditure for the research and development projects. Therefore, registration expenses for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.